FGR Diagnostic Criteria in Predicting Adverse Neonatal Outcomes

计划入组 50 人 · 首次发布于 2021 年 6 月 21 日

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

计划入组 102 人 · 首次发布于 2015 年 9 月 10 日

Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis

计划入组 511 人 · 首次发布于 2011 年 8 月 29 日

TGR-63

OGB-21501

Org-8484

Ohr Pharmaceutical, Inc.

United States

OUR EVENTORS PTY LTD

Australia

OUR LADY OF THE LAKE HOSPITAL, INC.

United States

Genentech Triples Lobbying Spend to $1.81M as Medicare Drug Price Negotiations Intensify

OGRD Alliance Expands Phospholipoproteomic Platform Across Asia and MENA Regions

OGRD Alliance Announces PLPC-DB Non-Cellular Oncology Immunotherapy Platform for Global Acquisition